Fulgent Genetics, Inc. (NASDAQ: FLGT) announced today, 2025‑10‑20, that it will present preliminary data from its ongoing Phase 2 trial of FID‑007 in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma. The data cutoff was September 25, 2025, and the presentation will take place at the European Society for Medical Oncology (ESMO) conference in Berlin, Germany, from October 17‑21, 2025.
FID‑007 is a nanoencapsulated paclitaxel formulated with a polyethyloxazoline (PEOX) polymer excipient. The design improves the drug’s water solubility, reduces formulation‑related toxicity, and enhances therapeutic efficacy by increasing tumor penetration and retention through the enhanced permeability and retention effect.
Chairman and CEO Ming Hsieh stated that the preliminary data reinforce Fulgent’s mission to deliver comprehensive solutions across the cancer care continuum, from early detection and diagnostics to drug development. The announcement marks a significant milestone in the company’s therapeutic pipeline and provides the first clinical evidence for a candidate that could generate future revenue streams.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.